Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018

Poster presentations will include new analysis of efficacy against drug resistant S. aureus in skin infections
BOSTON, June 07, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented at the American Society for Microbiology’s annual ASM Microbe 2018 meeting taking place from June 7-11 in Atlanta, GA. The data continue to highlight the robust efficacy and safety profile of omadacycline, an investigational once-daily oral and intravenous (IV) monotherapy antibiotic for the treatment of community-acquired infections including community-acquired bacterial pneumonia (CABP) and acu…


Leave a Reply

Your email address will not be published.